Skip to main content

Closed

GTBP: GT Biopharma, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-205.0%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage-211.7×

Current ratio3.69×

GT Biopharma, Inc.

GTBPNASDAQ Capital Market·USD·Closed

GT Biopharma, Inc.

GTBPNASDAQ·USD·Closed

$0.29

−4.65%

$0.29

−$0.01 (4.65%)

52W Range

2thpctl

Volume

0.40×avg

Mkt Cap

3.12MUSD

P/E

-0.0TTM

Div Yield

–ann

52W Range

2thpctl

Volume

0.40×avg

Market Cap

3.12MUSD

P/E Ratio

-0.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings